Long-term molecular remission with lenalidomide treatment of relapsed chronic lymphocytic leukemia.

Abstract

Lenalidomide is effective against relapsed chronic lymphocytic leukemia (CLL). We report the first case of long-term molecular remission with continuous lenalidomide treatment in a young patient with CLL relapsed to multiple treatments. Minimal residual disease was assessed by nested polymerase chain reaction on bone marrow samples with patient-specific primers. A 20-yr-old patient with standard-risk CLL was treated with lenalidomide after multiple relapses and achieved a 4 yr long complete molecular response with minimal toxicities. Published biologic data support that lenalidomide induces an immune-mediated control of CLL, and our case suggests that long-term treatment with lenalidomide is effective at a molecular level in patients with relapsed CLL.

• Authors: Francesco Spina, Francesca Rezzonico, Lucia Farina, Paolo Corradini
• Journal: European journal of haematology (Eur J Haematol) Vol. 90 Issue 4 Pg. 340-4 (Apr 2013) ISSN: 1600-0609 [Electronic] England
• PMID: 23281656 (Publication Type: Case Reports, Journal Article)
• Copyright: © 2013 John Wiley & Sons A/S.

Chemical References

• Antineoplastic Agents
• Complementarity Determining Regions
• Immunologic Factors
• Thalidomide
• Lenalidomide

Topics

• Adult
• Antineoplastic Agents (therapeutic use)
• Complementarity Determining Regions (genetics)
• Gene Rearrangement, B-Lymphocyte, Heavy Chain (genetics)
• Humans
• Immunologic Factors (therapeutic use)
• Lenalidomide
• Leukemia, Lymphocytic, Chronic, B-Cell (drug therapy, genetics, immunology)
• Male
• Neoplasm, Residual (drug therapy, genetics, immunology)
• Recurrence
• Remission Induction
• Thalidomide (analogs & derivatives, therapeutic use)
• Time Factors
• Young Adult